Richard Baldry from Roth Capital issued a price target of $7.00 for EGAN on 2026-09-08 00:07:28.The adjusted price target was set to $7.00.At the time of the announcement, EGAN was trading at $5.84.EGAN currently trades -63.39% versus its 52 week high of $15.95, and 5.41% compared to its 52 week low price of $5.41.Current 50...
Roth Capital analyst issues NEUTRAL recommendation for EGAN on September 8, 2026 12:07AM ET. EGAN was...
Key Points - Faruqi & Faruqi, LLP reminds Capricor investors of the September 28, 2026 deadline...
Vaxart, Inc. (VXRT) closed at $0.4950 on 130,592 shares, +0.5% on the session.The close landed 24%...
The Children's Place, Inc. (PLCE) - This analysis reviews how the stock price reacted after the...
Richard Baldry from Roth Capital issued a price target of $7.00 for EGAN on 2026-09-08 00:07:28.The adjusted price target was set to $7.00.At the time of the announcement, EGAN was...
from D.A. Davidson issued a price target of $22.00 for MAMA on 2026-09-04 13:04:14.The adjusted price target was set to $22.00.At the time of the announcement, MAMA was trading at...
Ted Jackson from Northland Securities issued a price target of $16.00 for MTRX on 2026-09-04 12:52:50.The adjusted price target was set to $16.00.At the time of the announcement, MTRX was...
from Lake Street issued a price target of $22.00 for MAMA on 2026-09-04 12:49:05.The adjusted price target was set to $22.00.At the time of the announcement, MAMA was trading at...
from Lake Street issued a price target of $16.00 for AOUT on 2026-09-04 12:38:15.The adjusted price target was set to $16.00.At the time of the announcement, AOUT was trading at...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
